Jefferies Reiterates a Buy Rating on Exact Sciences Corporation (EXAS)

Exact Sciences Corporation (NASDAQ:EXAS) is one of the best strong buy growth stocks to buy now. On August 21, Jefferies analyst Tycho Peterson reiterated a Buy rating on Exact Sciences Corporation (NASDAQ:EXAS) and set a price target of $80.00.

Exact Sciences (EXAS): Among Billionaire George Soros’ Small-Cap Stocks with Huge Upside Potential

Exact Sciences Corporation (NASDAQ:EXAS) reported its fiscal Q2 2025 earnings on August 6, announcing a record total revenue of $811 million for the quarter, up 16% on a reported and core revenue basis.

The company raised its full-year 2025 revenue and adjusted EBITDA guidance midpoints by $55 million and $25 million, respectively, and also announced a multi-year productivity plan targeting $150 million in annual savings by 2026.

Exact Sciences Corporation (NASDAQ:EXAS) is a diagnostics and screening company that focuses on the early detection and prevention of particular types of cancer. It offers Cologuard, a non-invasive screening test for the early detection of colorectal cancer, pre-cancer, and Oncotype DX.

While we acknowledge the potential of EXAS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than EXAS and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.